Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment
Sponsored by Aventyn, Inc.
About this study
The primary objective of CHAPERONE solution is to evaluate the efficacy of engaging, assessing, and enabling long term treatment strategy with Health Artificial Intelligence (AI) Chatbot, Copilot, Large Language Model (LLM) and vital sign monitoring device in reducing CKM disease burden using an algorithm obtained from biomarkers and diagnostics utilizing remote sensor driven technology tools, care coordination and patient empowerment.
The interconnectedness between Diabetes, Heart disease and Kidney disease (Cardio Kidney Metabolic) has never been more important to recognize than the present day as the current data on the prevalence of this trifecta suggests an exponential increase in comorbidity, death, poor quality of life and a colossal economic burden on the society. Risk factors such as hypertension, high cholesterol, smoking, prediabetes states, obesity, unhealthy eating habits, lack of exercise, micro particle air pollution, high inflammatory markers, life stressors and genetics play a significant role in triggering the onset of these diseases and their complications. Half a Billion people in the world are expected to be having diabetes by 2023; another 150 million with prediabetes and one billion with hypertensi…
Where this study is enrolling (2)
- Call 602-200-0437
Arizona Heart Foundation
Phoenix, Arizona
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- I'm interested
Gilbert Cardiology
Gilbert, Arizona
Who can participate
Inclusion criteria
- ✓Men and women over 18 years of age are included
- ✓Eligible subjects must have one of the risk factor/ disease component of CKM:
- ✓Diabetes with A1C of 7.5 or higher;
- ✓or Heart disease with stent placement;
- ✓or Coronary Artery Bypass Graft (CABG) in the last 12 months;
- ✓or Chronic Kidney Disease (CKD) stage 2- 4
- ✓and, in those with Heart failure, a recent hospitalization within one week of enrollment is required
Exclusion criteria
- ✕Those subjects who are not willing to sign an informed consent
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.